Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.50 |
| ▸ | RARB | P10826 | 1/20 | 0.48 |
| ▸ | THRA | P10827 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | WDR5 | P61964 | 1/20 | 0.46 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4141214 | 0.94 | PLA2G2A (0.59) | PLA2G2ARARBTHRATHRBTP53 | |
| SCHEMBL1749419 | 0.90 | THRA (0.56) | PLA2G2ARARBTHRATHRBTP53 | |
| SCHEMBL7995915 | 0.90 | PLA2G2A (0.56) | PLA2G2ARARBTHRATHRBTP53 | |
| SCHEMBL2307486 | 0.85 | PLA2G2A (0.56) | PLA2G2ATHRATHRBPLA2G4B | |
| SCHEMBL2358713 | 0.84 | PLA2G2A (0.66) | PLA2G2ARARBTHRATHRBTP53 | |
| SCHEMBL1200906 | 0.84 | PLA2G2A (0.66) | PLA2G2ARARBTP53TSHRPLA2G4B | |
| SCHEMBL1201538 | 0.84 | PLA2G2A (0.66) | PLA2G2ARARBTP53TSHRPLA2G4B | |
| SCHEMBL1200970 | 0.84 | PLA2G2A (0.66) | PLA2G2ARARBTP53TSHRPLA2G4B | |
| SCHEMBL1108059 | 0.84 | PLA2G2A (0.66) | PLA2G2ARARBTP53TSHRPLA2G4B | |
| SCHEMBL1201453 | 0.84 | PLA2G2A (0.66) | PLA2G2ARARBTP53TSHRPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105337-A1 | ENTEROBACTIN CONJUGATES AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105337-A1 | ENTEROBACTIN CONJUGATES AND USES THEREOF | BTD, VIP, SLC10A2 | PLA2G2A 4650/4885RARB 2716/4885THRA 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.